Tags

Type your tag names separated by a space and hit enter

Diagnostic efficacy of the ELISA test for the detection of deamidated anti-gliadin peptide antibodies in the diagnosis and monitoring of celiac disease.
J Clin Lab Anal 2009; 23(3):165-71JC

Abstract

BACKGROUND AND AIM

We evaluated the diagnostic performance of an ELISA test for anti-gliadin IgA and IgG antibodies, which uses synthetic deamidated gliadin peptides (anti-gliadin antibodies, AGAs) as coating; the results were compared with a test that uses extracted gliadin (AGAe).

METHODS

The study was conducted on the sera of 144 patients suffering from celiac disease (CD), including 20 patients with IgA deficiency and 9 who were following a gluten-free diet (GFD), and 129 controls.

RESULTS

In the 115 CD patients (without IgA deficiency), the sensitivity of AGAe IgA and IgG was 32.2 and 60.9%, whereas that of AGAs IgA and IgG was 59.1 and 72.2%. The specificity for AGAe IgA and IgG, and AGAs IgA and IgG was 93.8 and 89.9%, and 96.9% and 99.2%, respectively. Of the 20 patients with CD and IgA deficiency, 7 tested positive for AGAe IgG and 14 for AGAs IgG. The test using deamidated gliadin peptides performed better in terms of sensitivity and specificity than the AGA tests with extracted antigen.

CONCLUSIONS

The very high specificity of the AGAs IgG test (99.2%) also suggests that patients who test positive with this assay require a thorough followup, even if the anti-tissue transglutaminase antibodies (anti-tTG) and anti-endomysial autoantibodies (EMA) assays are negative.

Authors+Show Affiliations

Immunopatologia e Allergologia Azienda Ospedaliero-Universitaria S. Maria della Misericordia di Udine, Udine, Italy. tonutti.elio@aoud.sanita.fvg.it

Pub Type(s)

Evaluation Studies
Journal Article

Language

eng

PubMed ID

19455636

Citation

Tonutti, Elio, et al. "Diagnostic Efficacy of the ELISA Test for the Detection of Deamidated Anti-gliadin Peptide Antibodies in the Diagnosis and Monitoring of Celiac Disease." Journal of Clinical Laboratory Analysis, vol. 23, no. 3, 2009, pp. 165-71.
Tonutti E, Visentini D, Picierno A, et al. Diagnostic efficacy of the ELISA test for the detection of deamidated anti-gliadin peptide antibodies in the diagnosis and monitoring of celiac disease. J Clin Lab Anal. 2009;23(3):165-71.
Tonutti, E., Visentini, D., Picierno, A., Bizzaro, N., Villalta, D., Tozzoli, R., ... Brusca, I. (2009). Diagnostic efficacy of the ELISA test for the detection of deamidated anti-gliadin peptide antibodies in the diagnosis and monitoring of celiac disease. Journal of Clinical Laboratory Analysis, 23(3), pp. 165-71. doi:10.1002/jcla.20313.
Tonutti E, et al. Diagnostic Efficacy of the ELISA Test for the Detection of Deamidated Anti-gliadin Peptide Antibodies in the Diagnosis and Monitoring of Celiac Disease. J Clin Lab Anal. 2009;23(3):165-71. PubMed PMID: 19455636.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Diagnostic efficacy of the ELISA test for the detection of deamidated anti-gliadin peptide antibodies in the diagnosis and monitoring of celiac disease. AU - Tonutti,Elio, AU - Visentini,Daniela, AU - Picierno,Alessia, AU - Bizzaro,Nicola, AU - Villalta,Danilo, AU - Tozzoli,Renato, AU - Kodermaz,Graziano, AU - Carroccio,Antonio, AU - Iacono,Giuseppe, AU - Teresi,Saverio, AU - La Chiusa,Stella Maria, AU - Brusca,Ignazio, PY - 2009/5/21/entrez PY - 2009/5/21/pubmed PY - 2009/8/28/medline SP - 165 EP - 71 JF - Journal of clinical laboratory analysis JO - J. Clin. Lab. Anal. VL - 23 IS - 3 N2 - BACKGROUND AND AIM: We evaluated the diagnostic performance of an ELISA test for anti-gliadin IgA and IgG antibodies, which uses synthetic deamidated gliadin peptides (anti-gliadin antibodies, AGAs) as coating; the results were compared with a test that uses extracted gliadin (AGAe). METHODS: The study was conducted on the sera of 144 patients suffering from celiac disease (CD), including 20 patients with IgA deficiency and 9 who were following a gluten-free diet (GFD), and 129 controls. RESULTS: In the 115 CD patients (without IgA deficiency), the sensitivity of AGAe IgA and IgG was 32.2 and 60.9%, whereas that of AGAs IgA and IgG was 59.1 and 72.2%. The specificity for AGAe IgA and IgG, and AGAs IgA and IgG was 93.8 and 89.9%, and 96.9% and 99.2%, respectively. Of the 20 patients with CD and IgA deficiency, 7 tested positive for AGAe IgG and 14 for AGAs IgG. The test using deamidated gliadin peptides performed better in terms of sensitivity and specificity than the AGA tests with extracted antigen. CONCLUSIONS: The very high specificity of the AGAs IgG test (99.2%) also suggests that patients who test positive with this assay require a thorough followup, even if the anti-tissue transglutaminase antibodies (anti-tTG) and anti-endomysial autoantibodies (EMA) assays are negative. SN - 1098-2825 UR - https://www.unboundmedicine.com/medline/citation/19455636/Diagnostic_efficacy_of_the_ELISA_test_for_the_detection_of_deamidated_anti_gliadin_peptide_antibodies_in_the_diagnosis_and_monitoring_of_celiac_disease_ L2 - https://doi.org/10.1002/jcla.20313 DB - PRIME DP - Unbound Medicine ER -